Observational studyEuropean journal of neurology2026
Epidemiology of Progressive Supranuclear Palsy in Navarre, Spain: A Population-Based Study.
Observational study in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEpidemiological studies carried out on progressive supranuclear palsy (PSP) provide heterogeneous data. Our aim has been to analyze incidence, point prevalence, survival, and time to diagnosis of PSP in Navarre, a northern Spanish region.
methodsThis is a population-based observational retrospective study from 2010 to 2022. Data from various sources of health information were reviewed to identify all potential diagnoses of PSP, validated through medical records reviews. Patients were included if they fulfilled the 2017 Movement Disorder Society (MDS) criteria and were classified into the different PSP phenotypes.
resultsA total of 226 prevalent PSP cases were identified. Age-standardized point prevalence rate at January 1, 2023, was 7.52/100,000 inhabitants, and age-standardized annual incidence rate (IR) for the period was 2.41/100,000 person-years. PSP-Richardson syndrome (RS) phenotype showed significantly higher prevalence and incidence rates compared to PSP non-RS phenotypes. Joinpoint regression for overall incidence showed a significant increase until 2018 and thereafter a significant steep decline. Joinpoint regression for prevalence showed a statistically significant annual decline from 2018 onwards. Mortality rate experienced a peak in 2020. Median time to diagnosis was 37 months, and the median survival from clinical symptom onset was 89 months. PSP-RS was associated with reduced time to diagnosis and reduced survival compared to the PSP non-RS phenotypes.
conclusionsThis study represents the first population-based epidemiological study of PSP in Spain and the first with application of the new MDS diagnostic criteria in Europe, providing detailed incidence, prevalence, and mortality data that are in accordance with other European studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.